MOSCOW (MRC) -- Celanese Corporation, a global technology and specialty materials company, has presented innovations in ethylene-vinyl-acetate (EVA) polymers, the company's press release.
"Celanese is working with its customers to develop state-of-the-art drug delivery systems using our pharmaceutical material solutions," said Susan Rahe, global business director, Celanese EVA polymers business. "VitalDose EVA polymers offer pharmaceutical companies flexibility in product design to supply excipients that can be formulated to meet demanding release criteria and regulatory requirements."
"Our broad medical and pharmaceutical polymer portfolio is creating comfortable and easy-to-use drug delivery devices and implants," said Kelsey Achenbach, strategic marketing manager for the Celanese EVA polymers business. "Improving patient care has led to recent innovations in our EVA polymer portfolio that are creating broader device and implant design options to meet changing drug delivery needs."
VitalDose EVA - acontrolled-release excipient ideal for use in pharmaceutical drug delivery implants that require a consistent release of active ingredients. VitalDose EVA polymers may be used alone or in combination with other excipients and/or additives to achieve desired release-rate profiles.
As MRC reported previously, Celanese last increased its EVA and LDPE prices on 1 May 2016, as follows: prices of Ateva EVA grew by USD50/tonne for Asia, whereas LDPE prices went up by USD0.04/lg (USD 0.09/kg or USD90/tonne) for North and South America and by USD50/tonne for Asia.
Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of USD5.7 billion.
mrcpast.com